Aaron Edwards is the Co-founder & CEO of KiraGen Therapeutics, a biotech company engineering multiplex-edited cell therapies to overcome the tumor microenvironment in solid tumors. Prior to founding KiraGen, he led in vitro biology for Beam Therapeutics’ BEAM-201 program and contributed to immunology and gene editing efforts at Bluebird Bio. Aaron holds an MS/MBA in Biotechnology from Harvard Business School and GSAS and is a Henri Termeer Fellow and Blavatnik Fellow in Life Science Entrepreneurship.